Medical Affairs Podcast: Increasing Diversity in Clinical Trials

A lack of participant diversity in clinical trials exacerbates health disparity by limiting the applicability of new drugs to marginalized groups. In the latest Medical Affairs Podcast, host Garth Sundem speaks with Stacey Rivkin, Vice President of Client Solutions and Strategy at H1, about the challenge of increasing the diversity of participants in clinical trials.

According to Rivkin, “There’s so many different aspects of why, right, of why clinical trials have traditionally lacked diversity, there’s historical barriers, there have been access barriers, there are awareness barriers and prioritization barriers that the pharmaceutical companies haven’t necessarily always acknowledge. One of the I think one of the impacts of the FDA’s new guidance on requiring diversity in clinical trials is what’s really finally, bringing this to the forefront. People have known this has been an issue for a long time. But it took the FDA guidance to really make the industry act more than anything.”

Listen to the podcast and find the full transcript by clicking here.

(Source: Medical Affairs Podcast, January 5^th, 2022)